Glucocorticoids, cytokines and brain abnormalities in depression.
Major depression (MD) is a common psychiatric disorder with a complex and multifactor aetiology. Potential mechanisms associated with the pathogenesis of this disorder include monoamine deficits, hypothalamic-pituitary-adrenal (HPA) axis dysfunctions, inflammatory and/or neurodegenerative alterations. An increased secretion and reactivity of cortisol together with an altered feedback inhibition are the most widely observed HPA abnormalities in MD patients. Glucocorticoids, such as cortisol, are vital hormones that are released in response to stress, and regulate metabolism and immunity but also neuronal survival and neurogenesis. Interestingly depression is highly prevalent in infectious, autoimmune and neurodegenerative diseases and at the same time, depressed patients show higher levels of pro-inflammatory cytokines. Since communication occurs between the endocrine, immune and central nervous system, an activation of the inflammatory responses can affect neuroendocrine processes, and vice versa. Therefore, HPA axis hyperactivity and inflammation might be part of the same pathophysiological process: HPA axis hyperactivity is a marker of glucocorticoid resistance, implying ineffective action of glucocorticoid hormones on target tissues, which could lead to immune activation; and, equally, inflammation could stimulate HPA axis activity via both a direct action of cytokines on the brain and by inducing glucocorticoid resistance. In addition, increased levels of pro-inflammatory cytokines also induce the production of neurotoxic end products of the tryptophan-kynurenine pathway. Although the evidence for neurodegeneration in MD is controversial, depression is co-morbid with many other conditions where neurodegeneration is present. Since several systems seem to be involved interacting with each other, we cannot unequivocally accept the simple model that glucocorticoids induce neurodegeneration, but rather that elevated cytokines, in the context of glucocorticoid resistance, are probably the offenders. Chronic inflammatory changes in the presence of glucocorticoid resistance may represent a common feature that could be responsible for the enhanced vulnerability of depressed patients to develop neurodegenerative changes later in life. However, further studies are needed to clarify the relative contribution of glucocorticoids and inflammatory signals to MD and other disorders.
Zunszain
Patricia A
PA
Stress, Psychiatry and Immunology Laboratory (SPI-Lab), Department of Psychological Medicine, Institute of Psychiatry, King's College London, 125 Coldharbour Lane, SE59NU London, United Kingdom. patricia.zunszain@kcl.ac.uk
Anacker
Christoph
C
Cattaneo
Annamaria
A
Carvalho
Livia A
LA
Pariante
Carmine M
CM
D000818:Animals; D001921:Brain / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology*; D016207:Cytokines / Q000276:immunology / Q000378:metabolism*; D003863:Depression / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology*; D005260:Female; D005938:Glucocorticoids / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D007249:Inflammation / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D009410:Nerve Degeneration / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology; D019636:Neurodegenerative Diseases / Q000378:metabolism
D016207:Cytokines; D005938:Glucocorticoids
Oncogene. 2006 Oct 30;25(51):6758-80
17072327
Ann N Y Acad Sci. 1999;896:30-47
10681886
J Neurosci. 2003 Jul 2;23(13):5536-44
12843254
Br J Psychiatry. 2009 Aug;195(2):102-8
19648538
J Psychosom Res. 2007 Aug;63(2):131-5
17662748
J Neuroendocrinol. 2003 Aug;15(8):811-2
12834443
PLoS One. 2009;4(1):e4266
19180238
Neuron. 2009 May 28;62(4):479-93
19477151
Front Neuroendocrinol. 1993 Apr;14(2):76-122
8387436
Ann N Y Acad Sci. 2009 Oct;1179:167-78
19906239
J Clin Psychiatry. 2000;61 Suppl 6:4-6
10775017
Neuroscience. 2005;135(3):659-78
16154288
Endocrinology. 1999 Sep;140(9):4359-66
10465310
Mol Psychiatry. 2008 Jul;13(7):717-28
17700577
J Psychopharmacol. 2006 Jul;20(4 Suppl):79-84
16785275
Mol Psychiatry. 2005 Apr;10(4):332-3
15655564
Biol Psychiatry. 2003 Sep 1;54(5):499-503
12946878
Semin Neonatol. 2003 Feb;8(1):83-91
12667833
Am J Psychiatry. 2003 Oct;160(10):1890-1
14514508
Stress. 2008 Nov;11(6):411-24
19065455
Am J Psychiatry. 1971 Jul;128(1):31-40
4949651
Genes Brain Behav. 2008 Feb;7 Suppl 1:28-42
18184368
Mol Psychiatry. 2010 Apr;15(4):404-14
19773812
Neuropsychopharmacology. 2008 Dec;33(13):3182-9
18368033
Eur Arch Psychiatry Clin Neurosci. 1992;241(5):317-22
1606197
Science. 1984 Dec 14;226(4680):1342-4
6334362
Brain Behav Immun. 2009 Aug;23(6):750-4
19258033
Neuropsychopharmacology. 2009 Feb;34(3):747-58
18784648
Prog Brain Res. 2007;163:339-54
17765728
Eur J Neurosci. 2001 Nov;14(10):1603-12
11860455
Arch Gen Psychiatry. 1992 May;49(5):384-7
1586274
J Psychiatry Neurosci. 2009 Jan;34(1):41-54
19125212
Psychosom Med. 2009 Feb;71(2):171-86
19188531
Med Hypotheses. 1991 Aug;35(4):298-306
1943879
Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):751-6
18178625
Brain Res Rev. 2009 Oct;61(2):105-23
19481572
Brain Behav Immun. 2010 Jan;24(1):19-30
19647070
Biol Psychiatry. 2001 Mar 1;49(5):391-404
11274650
Biol Psychiatry. 2004 Aug 1;56(3):137-9
15271580
Biol Psychiatry. 2009 May 1;65(9):732-41
19150053
Metabolism. 2005 May;54(5 Suppl 1):20-3
15877308
Neuroimmunomodulation. 2009;16(5):300-17
19571591
Nat Rev Neurosci. 2005 Jun;6(6):463-75
15891777
CNS Drugs. 2005;19(2):105-23
15697325
Biol Psychiatry. 2003 Aug 1;54(3):338-52
12893109
Psychol Med. 1994 Feb;24(1):167-77
8208882
Biol Psychiatry. 2004 Nov 1;56(9):640-50
15522247
Neurosci Biobehav Rev. 2009 Mar;33(3):355-66
18996146
Br J Psychiatry. 1994 Mar;164(3):365-71
7832833
Med Hypotheses. 2003 Nov-Dec;61(5-6):519-25
14592780
Psychopharmacology (Berl). 2006 Dec;189(2):225-35
17016711
Neuroscience. 2009 Jan 23;158(2):823-32
19007863
Mol Cell Endocrinol. 2009 Mar 5;300(1-2):2-6
18840500
J Psychiatry Neurosci. 2009 Jan;34(1):4-20
19125209
Arch Gen Psychiatry. 2003 Dec;60(12):1248-55
14662557
Adv Exp Med Biol. 1999;461:107-16
10442170
Psychol Med. 2010 Jan;40(1):1-4
19335939
Nat Neurosci. 2007 Sep;10(9):1110-5
17726477
Br J Psychiatry. 2004 Jul;185:5-10
15231549
Prog Neurobiol. 2008 May;85(1):1-74
18346832
Neuropsychopharmacology. 2009 Oct;34(11):2376-89
19606083
Trends Immunol. 2006 Jan;27(1):24-31
16316783
Biol Psychiatry. 2008 Aug 15;64(4):293-301
18406399
Psychiatry Res. 1991 Aug;38(2):163-71
1661430
Mol Endocrinol. 2009 Mar;23(3):281-91
19095768
Curr Opin Psychiatry. 2008 May;21(3):290-5
18382230
J Neuroendocrinol. 2006 Jun;18(6):393-411
16684130
Biol Psychiatry. 2010 Mar 1;67(5):446-57
20015486
Front Neuroendocrinol. 2007 Aug-Sep;28(2-3):72-96
17544065
Schizophr Res. 2010 Feb;116(2-3):234-42
19751968
Am J Psychiatry. 2004 Apr;161(4):598-607
15056502
Immunol Allergy Clin North Am. 2009 May;29(2):285-93
19389582
Nat Rev Neurosci. 2008 Jan;9(1):46-56
18073775
Brain Behav Immun. 2007 Jan;21(1):9-19
17070667
Mol Psychiatry. 2000 May;5(3):262-9
10889528
Eur Neuropsychopharmacol. 2010 Jan;20(1):1-17
19748235
CNS Spectr. 2006 Dec;11(12 Suppl 15):12-21
17146414
J Affect Disord. 1982 Jun;4(2):93-101
6213695
Biol Psychiatry. 2004 Dec 1;56(11):819-24
15576057
Hippocampus. 2006;16(3):233-8
16411244
Mol Psychiatry. 2005 Jun;10(6):538-44
15494706
Neuropsychopharmacology. 2005 Oct;30(10):1923-31
15956995
J Clin Psychiatry. 1998;59 Suppl 14:11-4
9818625
Isr J Med Sci. 1995 Dec;31(12):705-12
8543464
Psychoneuroendocrinology. 2008 Jan;33(1):108-17
18037570
Cell. 2008 Feb 22;132(4):645-60
18295581
Nat Clin Pract Endocrinol Metab. 2007 Feb;3(2):168-79
17237843
Am J Psychiatry. 2004 Nov;161(11):1957-66
15514393
Biol Psychiatry. 2004 Aug 1;56(3):140-5
15271581
Eur Arch Psychiatry Clin Neurosci. 2007 Aug;257(5):250-60
17401728
Biol Psychiatry. 2008 Aug 15;64(4):266-72
18440494
Psychopharmacology (Berl). 2005 Oct;182(1):54-7
15991000
J Psychosom Res. 1966 Sep;10(2):189-95
5969513
Neuropsychopharmacology. 2007 Dec;32(12):2520-9
17356567
Mol Psychiatry. 2007 Nov;12(11):988-1000
17457312
Arch Gen Psychiatry. 2000 Oct;57(10):925-35
11015810
Mol Psychiatry. 2006 May;11(5):514-22
16415915
Neurochem Res. 2007 Oct;32(10):1749-56
17705097
Mol Psychiatry. 2009 May;14(5):511-22
18195714
Acta Psychiatr Scand. 1991 Oct;84(4):379-86
1746291
Psychopharmacology (Berl). 2008 Aug;199(2):231-44
18491079
J Psychiatry Neurosci. 2004 Jan;29(1):11-7
14719046
Endocr Rev. 1986 Aug;7(3):284-301
3527687
Mol Psychiatry. 2009 Dec;14(12):1095-104
18458677
Ann N Y Acad Sci. 2009 Oct;1179:86-105
19906234
Trends Neurosci. 2008 Sep;31(9):464-8
18675469
Metab Brain Dis. 2009 Mar;24(1):27-53
19085093
Int J Neuropsychopharmacol. 2002 Dec;5(4):389-99
12466037